Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19248179 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL1044990 | 0.92 | HSD11B1 (1.00) | HSD11B1HSD11B2 | |
| SCHEMBL5417587 | 0.91 | HSD11B1 (0.83) | HSD11B1HSD11B2 | |
| SCHEMBL2830494 | 0.91 | HSD11B1 (0.86) | HSD11B1HSD11B2 | |
| SCHEMBL2824187 | 0.90 | HSD11B1 (0.82) | HSD11B1HSD11B2 | |
| SCHEMBL1042152 | 0.87 | HSD11B1 (0.76) | HSD11B1HSD11B2 | |
| SCHEMBL2822512 | 0.86 | HSD11B1 (0.75) | HSD11B1HSD11B2 | |
| SCHEMBL2826303 | 0.86 | HSD11B1 (0.75) | HSD11B1HSD11B2 | |
| SCHEMBL2822516 | 0.86 | HSD11B1 (0.75) | HSD11B1HSD11B2 | |
| SCHEMBL2824670 | 0.85 | HSD11B1 (0.80) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269977-B1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBVIE INC (US) | 2016-04-27 | — | — | EP | claimed |
| US-9290444-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2016-03-22 | — | — | US | claimed |
| US-20150065508-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2015-03-05 | — | — | US | claimed |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBVIE INC. | 2013-03-07 | — | — | US | claimed |
| US-20130045978-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2013-02-21 | — | — | US | claimed |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | claimed |
| EP-2269977-A2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | Abbott Laboratories (US) | 2011-01-05 | — | — | EP | claimed |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2010-06-17 | — | — | US | claimed |
| US-20090192198-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | claimed |
| US-20090131434-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | claimed |
| US-7511175-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2009-03-31 | — | — | US | claimed |
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. | 2006-12-14 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| EP-1846363-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006074244-A2 | ADAMANTYL DERIVATIVES AS INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131434-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885 |
| US-20100152179-A9 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885 |
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | HSD11B1 241/4885HSD11B2 314/4885 |
| US-20060281773-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885 |
| US-20150065508-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | HSD11B1 214/4885HSD11B2 270/4885 |
| US-20090054426-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885 |
| US-20110159005-A1 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885 |
| US-20130059829-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CHAT, HSD17B1, ACHE | HSD11B1 5/4885HSD11B2 14/4885 |
| US-20090192198-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885 |
| US-20130045978-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885HSD11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.